“It is permitted to take the body and the life of a non-Jew.” – Babylonian Talmud, Sepher Ikkarim IIIc, 25
By Ido Efrati, HAARETZ, 11/26/2018
The study was conducted by Professor Ariel Darvasi, assistant dean of the Faculty of Life Sciences at the Hebrew University of Jerusalem, in coordination with Dr. Todd Lencz from The Feinstein Institute for Medical Research in New York. The first portion of the study included the largest-ever sample group of Ashkenazi Jews ever researched. Of the 2,500 Ashkenazi Jews from Israel who contributed DNA samples for the study, 1,500 were healthy, while 1,000 were affected by mental disorders related to schizophrenia.
The reason for choosing Ashkenazi Jews as the subject for the study, of all groups available, is rooted in the fact that Ashkenazi Jews are considered to be a an especially homogenous group, in terms of genetics. The limited genetic variation among Ashkenazi Jews allows for easy identification of differences between healthy and affected individuals. Professor Darvasi has studied Ashkenazi Jews for many years and employed the latest technology available to analyze the DNA samples he received for the study.
Current technology allows for very comprehensive DNA analysis and the ability to read millions of SNP points – basically, links in the DNA chain – at the same time, which makes for very effective scanning of DNA, Darvasi told Haaretz. During the first part of the study, the scientists checked for the prevalence of the NDST3 gene, which exists in 99.9% of the population. “But there are two specific variations of it that stand out among those with these disorders, Darvasi said. The results of the study found that Ashkenazi Jews who have the variations are 40 percent more likely to contract a schizophrenia-related disorder than those without it.
Checking the samples collected from Ashkenazi Jews was only the first part of the experiment. Following the compilation of thee results, the scientists began the second stage – a more comprehensive examination of other population groups. After we saw that the first sample was relevant, we continued to investigate the connection between the gene and the diseases among other populations from around the world. In the end, samples from over 25,000 people were checked, including people from Europe, Asia and Africa – which basically covers all the primary ethnicities of the human race, explained Darvasi.